Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Change in Account Payables (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Change in Account Payables for 6 consecutive years, with -$579374.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 133.34% to -$579374.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.4 million, a 292.39% decrease, with the full-year FY2024 number at -$578928.0, up 53.1% from a year prior.
  • Change in Account Payables was -$579374.0 for Q3 2025 at Ensysce Biosciences, down from $427537.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.1 million in Q2 2022 to a low of -$1.8 million in Q3 2022.
  • A 5-year average of -$78297.1 and a median of -$323538.0 in 2023 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: plummeted 865.92% in 2021, then skyrocketed 1071.15% in 2022.
  • Ensysce Biosciences' Change in Account Payables stood at -$170754.0 in 2021, then surged by 1071.15% to $1.7 million in 2022, then plummeted by 52.17% to $793088.0 in 2023, then tumbled by 165.73% to -$521262.0 in 2024, then fell by 11.15% to -$579374.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Change in Account Payables are -$579374.0 (Q3 2025), $427537.0 (Q2 2025), and -$741784.0 (Q1 2025).